Dr Haleh Shahidipour


Adjunct Fellow, School of Medicine


Haleh Completed her PhD in 2016 at the University of Liverpool, United Kingdom. Her PhD focused on the development of in vitro an in vivo models of Uveal Melanoma to improve understanding of the metastatic process, and provide a platform for the preliminary testing of potential new agents to aid molecular-based cancer therapy. She was awarded the Roy Mapstone Research Award for her work, and nominated for the MIT Outstanding Poster Award at the ARVO conference in Florida, USA. Following the completion of her PhD, she moved to Australia where she began her research with the team at Blacktown Clinical School and Research Centre. Her current research is focused on understanding the effect of the anti-diabetic drug Metformin on prostate cancer. She further plays a role in supporting and contributing to the teams establishment, development and research progress.

Qualifications and Recognition

  • PhD University of Liverpool, UK
  • MRes University of Liverpool, UK
  • BSc (Hons) University of Liverpool, UK

Contact Details